Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details Textual)

Commitments and Contingencies (Details Textual) - USD ($)					1 Months Ended			12 Months Ended
	Jan. 09, 2017	Aug. 04, 2016	Feb. 27, 2014	Jul. 24, 2012	Sep. 30, 2016	Aug. 31, 2016	Jun. 15, 2012	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Feb. 16, 2016	Sep. 30, 2014
Commitments and Contingencies (Textual)
Research recorded fees								$ 17,501,364	$ 13,311,739	$ 12,267,313
Cost of lease agreement						$ 2,400		17,000
Accounts payable and accrued liabilities								4,194,874	1,473,936
Manufacturing Agreement [Member]
Commitments and Contingencies (Textual)
Project estimated cost			$ 6,800,000					2,600,000
Non - refundable institutional fee			$ 600,000
Total project estimated to cost								100,000	100,000
Research and development costs								700,000
Services fees									4,200,000
Payments for materials										3,600,000
Einstein [Member]
Commitments and Contingencies (Textual)
Total project estimated to cost												$ 200,000
Research and development costs								37,000	100,000	100,000
CRO Agreement [Member]
Commitments and Contingencies (Textual)
Project estimated cost		$ 4,600,000						1,000,000
AbbVie Biotherapeutics Corp [Member] \| Product Development and Patent License Agreement [Member]
Commitments and Contingencies (Textual)
License fee payment								3,000,000
Milestones payments								$ 7,750,000
Description of royalty payment								The Company shall pay to AbbVie Biotherapeutics Corp. on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.
Royalty of net sales percentage								12.00%
First commercial sale period								12 years 6 months
AbbVie Biotherapeutics Corp [Member] \| After first net sales [Member]
Commitments and Contingencies (Textual)
Milestones payments								$ 1,500,000
AbbVie Biotherapeutics Corp [Member] \| Phase I Clinical Trial of a licensed product [Member]
Commitments and Contingencies (Textual)
Milestones payments				$ 750,000				750,000
Accounts payable and accrued liabilities								750,000
AbbVie Biotherapeutics Corp [Member] \| Phase II Clinical Trial of a licensed product [Member]
Commitments and Contingencies (Textual)
Milestones payments								750,000
Research and development costs					$ 750,000
Abbott Biotherapeutics Corp [Member] \| After first net sales [Member] \| Product Development and Patent License Agreement [Member]
Commitments and Contingencies (Textual)
Net sales in milestones payment								10,000,000
Oak Ridge National Laboratory [Member]
Commitments and Contingencies (Textual)
Research and development costs								$ 1,000,000	800,000	600,000
Oak Ridge National Laboratory [Member] \| Subsequent Event [Member]
Commitments and Contingencies (Textual)
Research and development costs	$ 700,000
Icon Clinical Research [Member]
Commitments and Contingencies (Textual)
Down payment of project estimated cost percentage								12.50%
Down payment for project								$ 1,900,000
Down payment paid in 2007 and 2012								200,000
Total project estimated to cost								2,700,000
Research and development costs								$ 800,000	400,000	400,000
Fred Hutchinson Cancer Research Center [Member] \| license and sponsored research agreement [Member]
Commitments and Contingencies (Textual)
Milestones payments							$ 1,000,000
Description of royalty payment								Royalty payments of 2% of net sales will be due to FHCRC.
Fund for Fred Hutchinson Cancer Research Center lab ( Per year for the first two years )							200,000
Fund for Fred Hutchinson Cancer Research Center lab ( thereafter )							300,000
Research recorded fees								$ 400,000	$ 300,000	$ 200,000
Fred Hutchinson Cancer Research Center [Member] \| Maximum [Member] \| license and sponsored research agreement [Member]
Commitments and Contingencies (Textual)
Clinical trial cost for approval of food and drug administration							23,500,000
Fred Hutchinson Cancer Research Center [Member] \| Minimum [Member] \| license and sponsored research agreement [Member]
Commitments and Contingencies (Textual)
Clinical trial cost for approval of food and drug administration							$ 13,200,000
Medpace, Inc. [Member] \| CRO Agreement [Member]
Commitments and Contingencies (Textual)
Total project estimated to cost											$ 7,200,000
Research and development costs								$ 2,600,000